GLP-1semaglutidetirzepatideosteoarthritiscost-effectiveness

Annals study weighs cost-effectiveness of semaglutide, tirzepatide in knee osteoarthritis

The modeling analysis by Smith, Losina and colleagues examines incretin therapy for patients who have both obesity and knee osteoarthritis.

By Maren Holt · Senior Reporter, GLP-1

Sep 30 20:00 ETSource: Annals of internal medicine

The wire

01Annals of Internal Medicine published a cost-effectiveness analysis of semaglutide and tirzepatide in patients with knee osteoarthritis and obesity.
02Payers and clinicians managing osteoarthritis increasingly face requests for incretin therapy as a weight-based alternative or adjunct to joint surgery.
03Cost-effectiveness models depend heavily on assumed drug prices and durability of weight loss, both of which are moving targets.

From the source

The Cost-Effectiveness of Semaglutide and Tirzepatide for Patients With Knee Osteoarthritis and Obesity
Annals of internal medicine · 2026 Oct · Smith KC, Losina E et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42896210/